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The increased vancomycin minimum inhibitory concentration values (MICs) for
methicillin-resistant Staphylococcus aureus (MRSA) isolates are associated with
treatment failure and mortality of MRSA infections. In the present study, 553 non-
duplicate MRSA isolates from various specimens of patients with infections at a
Chinese tertiary hospital from January 2003 to December 2014, were selected randomly
for investigating the shift of vancomycin MICs determined by E-test method. The
percentages of the MRSA isolates with vancomycin MICs of ≥2.0, 1.5, 1.0, and
≤0.75 mg/L were 16.3% (90/553), 38.5% (213/553), 35.6% (197/553), and 9.9%
(55/553), respectively. The highest geometric mean MIC (GM MIC) value (1.648 mg/L)
and the lowest GM MIC (0.960 mg/L) were found in the first year (2003) and the
last year (2014) over the study period, with significant difference (p < 0.05). The GM
MICs over the study period fluctuated by year, with the elevated values in 2005, 2011,
and 2013 and the decreased values in other years relative to the respective former
year. The vancomycin GM MIC (1.307 mg/L) for MRSA isolates from sputum was the
highest relative to that for the MRSA isolates from other specimens. By contrast, the
vancomycin GM MIC value (1.156 mg/L) for MRSA isolates from pus was the lowest,
with similar value to that for the isolates from blood. The vancomycin GM MICs in period
I (2003–2005), period II (2006–2008), period III (2009–2011), and period IV (2012–2014)
were 1.501, 1.345, 1.177, and 1.139 mg/L, respectively, with the continuous decreased
trend. Compared with period I, the vancomycin GM MIC for MRSA isolates in period IV
was significantly lower (p < 0.01), with a 1.318- fold decrease. The percentages of the
isolates with vancomycin MIC ≥2 mg/L in four periods were 25, 15.6, 15.2, and 12%,
respectively, with a continuous decrease. While the percentages of the isolates with
vancomycin MIC ≤0.75 mg/L in four periods increased from 1.7% in period I to 19.3%
in period IV. Taken together, a decreased trend in vancomycin MICs for MRSA isolates
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from a Chinese tertiary teaching hospital has been found. This pnenomenon was mainly
associated with a decrease in the proportion of the MRSA isolates with vancomycin MIC
≥2 mg/L and an increase in the proportion of the MRSA isolates with vancomycin MIC
0.75 mg/L.≤
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INTRODUCTION
Staphylococcus aureus, particularly MRSA, is an important cause
of infections including skin and soft tissue infections, foreign-
body infections, pneumonia, septic arthritis, endocarditis,
osteomyelitis, sepsis, and bloodstream infections both in
hospitals and community settings (David and Daum, 2010). Since
the first European isolate of MRSA was detected in 1960s, MRSA
infections have become a global concern (Cohen, 2007). In the
USA, the mortality caused by MRSA infections had surpassed
that caused by acquired immunodeficiency syndrome, hepatitis,
or tuberculosis (Klevens et al., 2007). Up to now, the treatment
of MRSA infections mainly depends on glycopeptide antibiotics.
Vancomycin, a representative of glycopeptide antibiotics, is often
used for treating MRSA infections (Levine, 2006). However, the
emergence of VISA, hVRSA, and VRSA results in the failure
of vancomycin treatment for serious MRSA infections, which is
becoming an important public health threat. Although, MRSA
isolates with intermediate or resistant to vancomycin remain
rare, many reports have described that the extensive use of
vancomycin resulted in the increase of vacomycin MICs values,
even near to 2 mg/L (Steinkraus et al., 2007; Soriano et al.,
2008; Dhand and Sakoulas, 2012). The increased vancomycin
MIC values for MRSA isolates were associated with treatment
failure and mortality (Martin et al., 2010). Because the high
failure rate of vancomycin treatment for MRSA infections is
associated with higher vancomycin MICs, the CLSI reduced the
vancomycin susceptibility breakpoint for S. aureus from MIC
value of 4–2 mg/L to improve the predictive susceptibility result
(CLSI, 2016). In China, although VRSA is not by far found, the
prevalence of hVRSA was more than 10% (Sun et al., 2009) and
VISA has been reported (Zhang et al., 2013; Zhu et al., 2015).
The elevated vancomycin MICs among MRSA clinical isolates in
China should be of concern. The primary objective of this study
was to evaluate the shift in vancomycin MICs for MRSA clinical
isolates over a 12-year period (2003–2014) at a tertiary teaching
hospital in China.
MATERIALS AND METHODS
Ethical Statement
The Ethics Committee of The First Affiliated Hospital of
Wenzhou Medical College exempted this study from review
because it focussed on bacteria.
Abbreviation: CLSI, Clinical and Laboratory Standards Institute; hVRSA, hetero-
resistant S. aureus; MIC, vancomycin minimum inhibitory concentration; MRSA,
methicillin-resistant Staphylococcus aureus; VISA, vancomycin-intermediate
S. aureus; VRSA, vancomycin-resistant S. aureus.
MRSA Clinical Isolates
From January 2003 to December 2014, a total of 553 MRSA
isolates (single isolate per patient) from various specimens of
patients at the First Affiliated Hospital of Wenzhou Medical
University located in Wenzhou, East China, were selected
randomly to investigate the shifts in vancomycin MICs. The
proportions of MRSA isolates isolated from various specimens
were as follows: 67.3% (372/553), sputum; 13.9% (77/553), pus;
6.5%(36/553), exudates; 5.1% (28/553), blood; 4.3% (24/553),
catheter and 2.8%(16/553), drainage. The over 12-year study
period was divided into four periods including period I
(2003–2005), period II (2006–2008), period III (2009–2011),
and period IV (2012–2014). Among 553 MRSA isolates,
the number of the MRSA isolates in period I (2003–2005),
period II (2006–2008), period III (2009–2011), and period
IV (2012–2014) were 116, 180, 79 and 158, respectively. The
clinical isolates were identified as S. aureus using VITEK-2
automatic microbiology analyzer (bioMérieux, Marcy-l’Étoile,
France). S. aureus ATCC 25923 was used as a control strain
for identification of bacteria. Cefoxitin disk diffusion was
used for detecting MRSA using MRSA N315 as a positive
control strain according to the guidelines provided by CLSI
(2016).
Antimicrobial Susceptibility Testing
Vancomycin MICs for MRSA isolates were determined by
E-test method (0.016–256 mg/L; AB bioMérieux, Marcy-
l’Étoile, France) in accordance with manufacturer’s guidelines.
Interpretive standards for vancomycin susceptibility for MRSA
isolates tested were in accordance with the guidelines provided by
CLSI (2016). S. aureus ATCC 29213 was used as a control train for
antimicrobial susceptibility testing. According to the guidelines
mentioned above, the S. aureus isolates with vancomycin
MICs ≤2 mg/L, 2< MICs ≤8 mg/L, and MICs >8 mg/L
were regarded as susceptible, intermediate, and resistant to
vancomycin, respectively.
Data Analysis and Statistical Methods
The MIC50 (MICs required to inhibit the growth of 50% of
organisms), MIC90 (MICs required to inhibit the growth of 90%
of organisms), MIC range, median MIC and geometric mean
MIC (GM MIC) were analyzed. Non-parametric correlation
(the Spearman’s ranking correlation coefficient) was used for
analyzing the shift in vancomycin MICs over 12-year period.
The trend in the proportion of MICs less than or equal to
the 2003 median MIC for each individual period was assessed
using Mantel–Haenszel X2 test. The statistical analyses were
accomplished using SPSS software (SPSS, Chicago, IL, USA).
p-Value with < 0.05 was considered statistical significance.
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RESULTS
Prevalence of MRSA Isolates
The prevalence of MRSA isolates in 12-year study period was
58.5% (553/946). The proportions of MRSA isolates among
period I (2003–2005), period II (2006–2008), period III (2009–
2011), and period IV (2012–2014) were 56.9% (116/204), 68.4%
(180/263), 51.0% (79/155), and 48.7% (158/324), respectively.
Vancomycin MIC-Related Parameters
among MRSA Isolates
Of 553 MRSA clinical isolates, 98.0% were susceptible to
vancomycin, while 2.0% (11 isolates) with vancomycin
MIC = 3 mg/L were intermediate susceptible to vancomycin.
The vancomycin MICs for 553 MRSA clinical isolates tested
ranged from 0.38 to 3.00 mg/L, with the GM MIC of 1.35 mg/L.
The percentages of the MRSA isolates with vancomycin MICs
of ≥2.0, 1.5, 1.0, and ≤0.75 mg/L were 16.3% (90/553), 38.5%
(213/553), 35.6% (197/553), and 9.9% (55/553), respectively. The
highest (1.648 mg/L) and the lowest GM MIC value (0.960 mg/L)
were found in the first year (2003) and the last year (2014) during
the study period. The vancomycin GM MICs over the study
period fluctuated by year, with the increased results in 2005,
2011, and 2013 and the decreased results in other years relative
to the respective former year. The vancomycin MIC-related
parameters among MRSA isolates from different specimens were
showed in Table 1. The vancomycin GM MIC value (1.307 mg/L)
for MRSA isolates from sputum was the highest relative to that
for the MRSA isolates from other specimens. By contrast, the
vancomycin GM MIC value (1.156 mg/L) for MRSA isolates
from pus was the lowest, with similar value to that for the isolates
from blood. The vancomycin MIC50 values for MRSA isolates
from pus and drainage were 1 mg/L, while those for MRSA
isolates from other specimens were 1.5 mg/L. The vancomycin
MIC90 values for MRSA isolates from blood and drainage were
1.5 mg/L. The isolates from sputum, pus, catheter and exudates
had vancomycin MIC90 value of 2 mg/L.
Comparison of Vancomycin MIC-Related
Parameters for MRSA Isolates in 4 Study
Periods
The vancomycin GM MIC values in period I (2003–2005), period
II (2006–2008), period III (2009–2011), and period IV (2012–
2014) were 1.501, 1.345, 1.177, and 1.139 mg/L, respectively, with
TABLE 2 | Vancomycin MIC-related parameters in four study periods
(mg/L).
Periods Geometric mean MIC MIC50 MIC90 MIC range
I (2003–2005) 1.501 1.5 2.0 0.75–3.0
II (2006–2008) 1.345 1.5 2.0 0.5–3.0
III (2009–2011) 1.177 1 2.0 0.38–3.0
IV (2012–2014) 1.139 1 2.0 0.38–3.0
the continuous decreased trend (Table 2). Compared with period
I, the vancomycin geometric mean MIC value for MRSA isolates
in period IV was significantly lower (p < 0.01), with a 1.318-
fold decrease. The vancomycin MIC50 values in period I and
period II were 1.5 mg/L, while those in the latter two periods were
1.0 mg/L. The vancomycin MIC90 values in four periods all were
2.0 mg/L. The vancomycin MIC for all MRSA isolates in 2003
was ≥1 mg/L, while only 66.7% of the isolates tested with MIC
≥1 mg/L were found in 2014. The percentage of MRSA isolates
with vancomycin MIC≥2 mg/L in 2003 was high to 45.5%, while
that was not found in 2014. The percentages of MRSA isolates
in four periods with different vancomycin MICs were showed in
Table 3. The percentages of the MRSA isolates with vancomycin
MIC ≥2 mg/L in period I (2003–2005), period II (2006–2008),
period III (2009–2011), and period IV (2012–2014) were 25, 15.6,
15.2, and 12%, respectively, with a gradual decrease. While the
percentages of the isolates with vancomycin MIC ≤0.75 mg/L in
four periods mentioned above increased from 1.7% in period I
to 19.3% in period IV (Table 3). The percentages of the isolates
with vancomycin MIC = 1 mg/L and MIC = 1.5 mg/L in four
periods fluctuated. The vancomycin MICs for 75% of the isolates
in period I, 84.4% of the isolates in period II, 84.8% of the isolates
in period III and 88% of the isolates in period IV were≤1.5 mg/L.
The percentages of MRSA isolates with MICs less than or equal to
median MIC (1.5 mg/L) in period I (2003–2005) in four periods
were 75, 84.4, 84.8, and 88%, respectively.
DISCUSSION
In recent years, a continuing increase in the prevalence of MRSA
has been found (Kock et al., 2010). Up to now, vancomycin is still
a standard first-line antibiotic for MRSA infections, but its MIC
creep for MRSA isolates is becoming a major concern. Soriano
et al. (2008) suggested that mortality of MRSA bacteremia was
significantly higher when vancomycin was empirically used for
TABLE 1 | Vancomycin MIC-related parameters of MRSA isolates from different specimens.
Specimens Geometric mean
MIC (mg/L)
MIC50
(mg/L)
MIC90
(mg/L)
MIC range
(mg/L)
MIC ≥2 mg/L
(%)
1 ≤ MIC < 2 mg/L
(%)
MIC <1 mg/L
(%)
Sputum 1.307 1.5 2 0.5–3 16.7 75.7 7.6
Pus 1.156 1 2 0.38–3 17.7 64.6 17.7
Blood 1.188 1.5 1.5 0.38–2 10.7 78.6 10.7
Catheter 1.261 1.5 2 0.38–3 20.0 64.0 16.0
Exudates 1.243 1.5 2 0.5–2 12.8 64.1 23.1
Drainage 1.247 1 1.5 1–2 6.3 93.7 0
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TABLE 3 | Percentages of MRSA isolates with different vancomycin MICs
(%).
Periods MIC
≤0.75 mg/L
MIC
= 1 mg/L
MIC
= 1.5 mg/L
MIC
≥2 mg/L
I (2003–2005) 1.7 19.8 53.5 25
II (2006–2008) 3.3 33.3 47.8 15.6
III (2009–2011) 12.7 44.3 27.8 15.2
IV (2012–2014) 19.3 35.9 32.8 12
treating infection caused by the strains with a high vancomycin
MIC (>1 mg/L). Lodise et al. (2008) reported that the median
hospital length of stay was longer for the patients infected by
MRSA isolates with vancomycin MIC ≥1.5 mg/L than that
with vancomycin MIC <1.5 mg/L (21 days versus 10.5 days,
respectively). In the present study, the percentage of MRSA
isolates with vancomycin MIC ≥1.5 mg/L was 55.6% and the
geometric mean MICs ranged from 0.96 to 1.648 mg/L over
12 years, which was higher than a previous report from China
among which vancomycin geometric mean MICs for 1411 MRSA
isolates from six hospitals between 2006 and 2011 were from
0.906 to 1.040 mg/L (Zhuo et al., 2013). Vancomycin MIC values
determined by E-test method were higher than those determined
by CLSI-recommended broth dilution, MicroScan and Sensititre
broth microdilution assays (Prakash et al., 2008; Pitz et al.,
2011). 11 MRSA isolates with vancomycin MIC = 3 mg/L
determined by E-test method in the present study were re-
determined to be vancomycin MIC = 3 mg/L determined by
CLSI-recommended broth micro-dilution. The reasons why the
vancomycin MIC values for MRSA isolates in the present study
were relatively higher may be associated with the application
of E-test method and the majority of MRSA isolates (67.3%,
372/553) from sputum with higher vancomycin geometric mean
MIC value relative to those from other specimens. However,
relatively higher vancomycin MIC values for MRSA isolates
found in the present study indicated the potential for treatment
failure of vancomycin for MRSA infections and should be of
concern.
Steinkraus et al. (2007) reported that the vancomycin MICs
for MRSA clinical isolates increased in from 2001 to 2005 at
a tertiary care institution in the USA. Increased vancomycin
MICs for S. aureus clinical isolates from 2000 to 2004 were
found in a American hospital (Wang et al., 2006). Previous
studies reported that a tendency toward decreased susceptibility
to vancomycin in MRSA isolates has reemerged in China (Zhuo
et al., 2013; Chang et al., 2015). However, many studies did
not find this increased trend (Sancak et al., 2013; Goldman
et al., 2014). No upward creep in vancomycin MICs for MRSA
isolates was found in the UK and Ireland from 2001 to 2007
(Reynolds et al., 2012). A report from Turkey also did not
detect a increase in vancomycin MICs among MRSA blood
isolates over an 11-year period (Sancak et al., 2013). The
SENTRY Antimicrobial Surveillance Program reported that there
was no evidence of increased vancomycin resistance during
1998–2003 (Jones, 2006). Musta et al. (2009) demonstrated that
the vancomycin MIC distribution was stable over an 11-year span
from 1996 to 2006. Alos et al. (2008) reported that no vancomycin
MIC creep from 2002 to 2006 was found in a setting with a
low usage of vancomycin. Interestingly, in the present study,
we observed a decreased trend of vancomycin MICs for MRSA
isolates across 12 years (2003–2014). Our results showed that
although vancomycin geometric mean MICs for MRSA isolates
fluctuated by year, it decreased continuously per 3 years. We
also applied frequency distributions of the MRSA isolates with
different MIC values and the percentages of MRSA isolates with
MICs less than or equal to 2003–2005 median MIC (1.5 mg/L)
to demonstrate a decrease in vancomycin MICs during the
study period. Although, the increased vancomycin MICs may be
associated with the application of E-test method, these results
were suitable for observing the shift in vancomycin MICs for
MRSA isolates for a long period. The decreased vancomycin
MICs in the present study were primarily associated with a
decrease in the proportion of the MRSA isolates with MIC
≥2 mg/L and an increase in the proportion of the isolates
with MIC ≤0.75 mg/L. Conflicting findings in vancomycin MIC
shift may be due to differences in the study periods, geographic
locations, use of new antibiotics, vancomycin usage densities,
number of enrolled cases, and MIC assays used. Kehrmann
et al. (2011) investigated bloodstream MRSA isolates at several
hospitals in two German cities from 2004 to 2009 and found that
the creep phenomenon varied by region. Unfortunately, we did
not acquire the accurate usage density of vancomycin for MRSA
infections during study period, which enable us not to know the
association between usage density of vancomycin and decreased
vancomycin MIC. We speculate that the pnenomenon found in
the present study was associated with enforced administration
of reasonable antimicrobials usage by Chinese government
and increased samples for bacteria culture. The limitations of
the present study included vancomycin MICs determined by
E-test method rather than the broth microdilution method and
unknown molecular lineages and a selection bias of MRSA
isolates.
Taken together, a decreased trend in vancomycin MICs for
MRSA isolates from a Chinese tertiary teaching hospital has
been found. This pnenomenon was primarily associated with
a decrease in the percentage of the MRSA isolates with MIC
≥2 mg/L and an increase in the percentage of the MRSA
isolates with MIC ≤0.75 mg/L. As fluctuation of vancomycin
MICs occurred in some years, a decreased trend in vancomycin
MICs for MRSA isolates found in the present study should be
further confirmed by continuous investigation in subsequent
years.
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